Functionalised SLNs-based nanovectors for gene therapy in Fabry diseaseThe liver as an α-Galactosidase A factory

  1. Rodríguez Castejón, J 12
  2. Gómez Aguado, I 12
  3. Beraza Millor, M 12
  4. Solinís, MA 12
  5. Del Pozo Rodríguez, A 12
  6. Rodríguez Gascón, A 12
  1. 1 Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents and Gene Therapy, 01006 Vitoria-Gasteiz,Spain
  2. 2 Pharmacokinetics, Nanotechnology & Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain
Revista:
RESCIFAR Revista Española de Ciencias Farmacéuticas

ISSN: 2660-6356

Año de publicación: 2021

Título del ejemplar: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA

Volumen: 2

Número: 2

Páginas: 46-48

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: RESCIFAR Revista Española de Ciencias Farmacéuticas

Resumen

Fabry disease (FD) is a monogenic X-linked metabolic disorder caused by mutations in the gene that encodes the enzyme α-Galactosidase A (α-Gal A). A deficiency of enzyme activity leads to a progressive deposition of glycosphingolipids within the lysosomes of cells, predominantly in vascular endothelial and smooth muscle cells. The liver is a highly specialized organ in protein synthesis, which, after transfection with the appropriate nucleic acid, could act as an α-Gal A production factory to later release it and restore the enzyme deficiency in affected organs. The delivery of nucleic acids to hepatocytes with non-viral vectors is challenging; however, it can be enhanced by functionalizing the carriers with different ligands. Solid Lipid Nanoparticles (SLNs) are regarded as one of the most promising non-viral gene delivery systems. One of their main advantages is the wide versatility they offer. In fact, SLNs can be decorated easily with polysaccharides to control the biodistribution in vivo. The objective of the present work is the design of SLNs-based nanovectors decorated with polysaccharides and the evaluation of their capacity to transfect a liver-derived cell line (Hep G2).

Fuente de los datos: Dialnet